丨 Friday, December 29, 2023 丨.
no.1Chinese Center for Disease Control and Prevention: Predicting JN1 variants pose a low public health risk
On December 28, the National Health Commission held a press conference on the prevention and treatment of respiratory diseases in winter. Peng Zhibin, director of the Department of Respiratory Infectious Diseases of the Infectious Disease Management Department of the Chinese Center for Disease Control and Prevention, introduced that recently, jnThe spread of the 1 variant is rising rapidly abroad and has become the main epidemic strain.
jn.The 1 variant belongs to the Omicron variant, and the World Health Organization recently assessed that based on the available evidence, jn1 is highly transmissible and immune evasive, but there is no evidence to suggest that it is more pathogenic. The cross-effect of previous infection and vaccination with XBB (Omicron subvariant variant) vaccine has a protective effect on it, and the public health risk is predicted to be low. Peng Zhibin said.
Comments:The New Year's Day and Spring Festival holidays are approaching, and the Spring Festival is about to begin, so you need to make arrangements in advance.
no.2 Two innovative drugs of Boan Biotech have been granted orphan drug designation by the FDA
On December 27, Boan Biotech announced that it had independently developed two targeting Claudin182. The innovative antibody BA1105 and the innovative antibody drug conjugate BA1301 have been granted orphan drug designation by the U.S. Food and Drug Administration for the indication of pancreatic cancer.
Comments:Orphan drugs, also known as rare disease drugs, refer to drugs used to prevent and diagnose rare diseases. The orphan drug designation of BA1105 and BA1301 is conducive to the company's reduction of R&D investment and acceleration of clinical development and marketing progress.
no.3Medical aesthetic concept stocks collectively strengthened yesterday
On December 28, medical cosmetology concept stocks collectively strengthened. As of **, Angelalign rose 834%, modern dentistry rose 617%, Sisram Medical Technology rose 674%。
Comments:Caixin** said that at the end of the year and the beginning of the year, the consumer demand for medical cosmetology may continue to be released, and the economic recovery trend will be superimposed, and the medical cosmetology track is likely to continue to pick up.
no.4 Astellas and Elpiscience have entered into a partnership
On December 28, Elpiscience announced that it has entered into a collaborative development and licensing agreement with Astellas for the new BIME (bispecific antibody macrophage engagger) platform and drug candidate ES019 and another molecule program.
Elpiscience will receive an upfront payment of $37 million and an exercise fee from Astellas. In addition, Elpiscience will receive additional R&D funding from Astellas to advance the project. Upon the exercise of all of Astellas' interests, Elpiscience will be eligible to receive potential development, regulatory and commercialization milestone payments totaling more than $1.7 billion. Elpiscience will also receive single-digit to double-digit percentage royalties on global net sales of licensed products.
Comments:The cooperation between the two parties is expected to accelerate the clinical progress and commercialization of the drug.
National Business Daily.